U.S. Stem Cell, Inc. (OTCQB: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced the opening of another regenerative clinic using its proprietary products and services, bringing the number of clinics using its technology to 287.
Regenerative Wellness Clinic (RWC), located in West Palm Beach, represents another addition to USRM's global distribution platform for its proprietary, stem cell technology, and is a direct result of USRM's position as the world's largest educator in stem cell innovation and physician training, with more than 700 USRM certified stem cell physicians globally.
"We are so pleased to hit this next milestone with Regenerative Wellness, and look forward to working closely with this incredible team of experts," said Mike Tomas, Chief Executive Officer of U.S. Stem Cell, Inc. "Partnering with RWC provides us the opportunity to expand our strategic goal of market penetration while maintaining scalability. This approach is in direct alignment with our longer-term strategy of establishing and maintaining profitability as we grow globally."
The minimally invasive, proprietary procedure - which utilizes a patient's own stem-cell-rich adipose or fat tissue - has, management believes, significantly boosted success rate for patient outcomes in a wide variety of indications including pain management, orthopedic, autoimmune, cardiac and other systemic conditions.
The West Palm Beach clinic is spearheaded by Dr. Rosemary Daly, an interventional spine/pain management physician, board certified in Anesthesiology and Pain Medicine. Dr. Daly graduated from the New York College of Osteopathic Medicine and completed her Anesthesiology residency at the Montefiore Medical Center at the Albert Einstein College of Medicine.
"Being able to offer U.S. Stem Cell's proprietary process to our patients means we will be able to make more advanced, successful regenerative treatments available to patients in South Florida," said Dr. Daly. "Moreover, we contend that the minimally invasive treatments applied in an outpatient procedure can help jumpstart the body's own healing capabilities and provide long-term relief - an advancement which has endless options in the world of pain management."
"Dr. Daly's expertise in reducing chronic and debilitating pain makes her a perfect partner for our expansion," said Dr. Kristin Comella, Chief Science Officer for U.S. Stem Cell, Inc. "We look forward to collaborating with the excellent researchers and physicians on Dr. Daly's team, as we continue to deepen our expertise of this ground-breaking, regenerative therapy."
U.S. Stem Cell's novel advancements in stem cell therapy, in managements' opinion, could be a significant alternative to the explosive opioid crisis in America - a direct result of America's failed attempt at pain management. According to The New York Times, published June 5, 2017, drug overdose is now the leading cause of death in the United States for patients under the age of 50, while the October 15, 2017 edition of 60 Minutes reports that the opioid crisis has claimed 200,000 lives in the United States over the past few decades.
U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry and has, to management's knowledge, completed more clinical treatments than any other stem cell company in the world in the past 20 years.
AI
